Current state of antioxidant use in Parkinson’s disease pharmacotherapy

Abaimov D.A., Zorina E.A., Shabalina A.A., Sychev D.A.

1) Russian Center for Neurology and Neurosciences, Moscow, Russia; 2) World-Class Genomic Research Center “Center for Predictive Genetics, Pharmacogenetics, and Personalized Therapy”, B.V. Petrovsky Russian Scientific Center of Surgery, Moscow, Russia; 3) Russian Medical Academy of Continuous Professional Education, Moscow, Russia

This review discusses the potential for the use of various antioxidants as neuroprotective agents in Parkinson’s disease (PD). Experimental studies of antioxidants in various laboratory models of parkinsonism are presented in detail. The main clinical trials of antioxidants as therapeutic agents in PD are also reviewed. This article is aimed to familiarization of readers with the current state of pharmacological research on antioxidants and the main challenges of their use in PD. The article demonstrates the potential of combining antioxidants with traditional PD therapy and highlights the main limitations associated with the use of antioxidants in clinical practice. 

For citations: Abaimov D.A., Zorina E.A., Shabalina A.A., Sychev D.A. Current state of antioxidant use in Parkinson’s disease pharmacotherapy. Pharmateca. 2026;33(6):22-33. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.6.22-33

Authors’ contribution: The authors contributed equally to all stages of the work and preparation of the article.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.

Keywords

About the Authors

Denis A. Abaimov, Cand. Sci. (Biol.), Senior Researcher, Head of the Pharmacokinetics Group, Department of Laboratory Diagnostics, Institute of Clinical and Preventive Neurology, Russian Center for Neurology and Neuroscience, Moscow, Russia; abaimov@neurology.ru, ORCID:
https://orcid.org/0000-0001-6888-3223, eLibrary SPIN: 7548-0933, Scopus Author ID: 22133763300 (corresponding author)
Ekaterina A. Zorina, Junior Researcher, Pharmacokinetics Group, Laboratory Diagnostics Department, Institute of Clinical and Preventive Neurology, Russian Center for Neurology and Neurosciences, Moscow, Russia; katuzorina@mail.ru, ORCID: https://orcid.org/0009-0000-9575-9308, eLibrary SPIN: 4303-0262, Scopus Author ID: 58181026900
Alla A. Shabalina, Dr. Sci. (Med.), Leading Researcher, Head of the Department of Laboratory Diagnostics, Institute of Clinical and Preventive Neurology, Russian Center for Neurology and Neuroscience, Moscow, Russia; shabalina@neurology.ru, ORCID: https://orcid.org/0000-0001-9604-7775, eLibrary SPIN: 9414-9068, Scopus Author ID: 26664964100
Dmitry A. Sychev, Dr. Sci. (Med.), Professor, Professor of the Russian Academy of Sciences, Academician of the Russian Academy of Sciences, Honored Scientist, Scientific Director of the World-Class Genomic Research Center «Center for Predictive Genetics, Pharmacogenetics and Personalized Therapy», B.V. Petrovsky Russian Scientific Center of Surgery; Head of the B.E. Votchal Department of Clinical Pharmacology and Therapy, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; dmitry.alex.sychev@gmail.ru, ORCID:
https://orcid.org/0000-0002-4496-3680, eLibrary SPIN: 4525-7556, Scopus Author ID: 7801389135

Similar Articles